Compare LCFY & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCFY | MBRX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.6M |
| IPO Year | 2022 | 2016 |
| Metric | LCFY | MBRX |
|---|---|---|
| Price | $2.86 | $3.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 14.3K | ★ 621.8K |
| Earning Date | 03-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,099,713.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.51 | $3.13 |
| 52 Week High | $13.98 | $91.25 |
| Indicator | LCFY | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.87 | 44.52 |
| Support Level | $3.01 | $3.13 |
| Resistance Level | $3.98 | $4.24 |
| Average True Range (ATR) | 0.20 | 0.40 |
| MACD | -0.05 | -0.34 |
| Stochastic Oscillator | 1.66 | 3.65 |
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.